HEPA Archives | BioTuesdays

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Developments

Hepion completes dosing in Phase 1b multiple ascending dose study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose (MAD) study of CRV431. The open-label MAD study was designed to assess...

September 1, 2020

Developments

Hepion to present CRV431 preclinical data at liver congress

Hepion Pharmaceuticals (NASDAQ:HEPA) will present a poster on CRV431’s antifibrotic activity at the Digital International Liver Congress 2020, taking place from Aug. 27-29. Dr. Joseph Kuo will present a preclinical...

August 27, 2020

Developments

Hepion CRV431 antiviral benefits published in PLOS ONE

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that the peer-reviewed journal, PLOS ONE, has published a paper highlighting the antiviral effects of CRV431. Co-authored by Hepion’s CSO, Dr. Daren Ure and CEO...

August 12, 2020

Developments

Hepion doses first patient with CRV431 in Phase 2 NASH study

Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first patient in its Phase 2 trial assessing CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2a study, called AMBITION, is designed to assess...

August 5, 2020

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the final dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 300 mg dosing level to be safe and...

June 29, 2020

Developments

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 demonstrated antifibrotic activity in an experimental model of renal fibrosis. The study, which was conducted by SMC Laboratories in Tokyo, Japan, evaluated CRV431 in the...

June 22, 2020

Executive Moves

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed industry veteran, Dr. Peter Wijngaard, to its board of directors. “Dr. Wijngaard provided invaluable guidance to Hepion’s management team during our earlier work on...

June 10, 2020

Tag - HEPA

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion CRV431 featured on The Bio Report podcast

Hepion completes dosing in Phase 1b multiple ascending dose study of CRV431

Hepion to present CRV431 preclinical data at liver congress

Hepion CRV431 antiviral benefits published in PLOS ONE

Hepion doses first patient with CRV431 in Phase 2 NASH study

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter